DURHAM, N.C.--(BUSINESS WIRE)--Argos Therapeutics today announced the presentation of two abstracts at the AIDS Vaccine 2009 conference, being held October 19-22 in Paris, France. Favorable immune response, viral load and safety data from the ongoing Phase 2a proof-of-concept trial of AGS-004 therapy for the treatment of HIV will be discussed. AGS-004 is a product of the Company’s Arcelis™ technology, and is a personalized, RNA-loaded dendritic cell-based immunotherapy that is perfectly matched to each patient’s unique HIV viral burden. The target population for the trial is HIV-1-infected patients with durable viral suppression from antiretroviral therapy (ART).
